AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 211 min read$ELVN

Hohl Benjamin sold $303K of ELVN

Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 shares of Enliven Therapeutics, Inc. (ELVN) at an average of $50.35 ($50.03–$51.49, $0.30M total) across 3 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hohl Benjamin
Published Sep 21, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ELVN
Neutral
medium confidence
Mentioned
$ELVN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ELVNNeutralLow
01

Why it matters

The disclosed sale reduces insider ownership but is unlikely to trigger a material price move.

02

Market read

Primary relevance is to ELVN shareholders; broader market impact is minimal.

03

What to watch

Potential upcoming clinical data releases or financing events not mentioned.

Relevance 3/10Novelty 4/10Timing: filed Sep 21, 2026

Background

Form 4 filings disclose insider transactions; a CFO sale via 10b5‑1 is routine but noteworthy for investors.

Company-level read

Ticker impact

$ELVNNeutralMedium confidence
Context

CFO Benjamin Hohl sold 6,018 shares for $303K via a 10b5‑1 plan, reducing his stake to 38,000 shares.

Expected impact

Minor downward pressure; likely limited to short‑term volatility.

Evidence & confidence

The sale size is modest relative to market cap and disclosed under a pre‑arranged plan, so market reaction is expected to be muted.

Market effects

Sector

None significant; insider sale does not affect biotech sector outlook.

Regional

No regional impact.

Global

Limited to ELVN shareholders.

Counterpoint

What could challenge this read

Sale could be a tactical move unrelated to company fundamentals; price may stay stable.

Key entities

  • Company
    Enliven Therapeutics, Inc.

    Biotech firm listed as ELVN.

  • Individual
    Benjamin Hohl

    Chief Financial Officer of Enliven Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ELVN insider trading history →

Related articles

OCT 1
$ELVNMed

Enliven Therapeutics stock initiated at Overweight by JPMorgan

JPMorgan initiated coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a $75 price target, implying 64% upside. The stock has surged 198% year-to-date. Analysts highlight ELVN-001's potential in treating chronic-phase CML, with U.S. peak sales estimated at $5 billion. Recent reports from William Blair, Barclays, and Guggenheim also show positive outlooks.

investing.com2 min
AUG 5
$ELVNMed

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics, Inc. (ELVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profile Reached alignme

SEC EDGAR 8-K6 min
JUN 12
$ELVNMedAI 8/10

Enliven Therapeutics Shares Rise 9%

Enliven Therapeutics (ELVN) shares rose 8.92% to $43.96 on Friday after the company priced an upsized public offering expected to raise about $400 million in gross proceeds, according to the article. Enliven sold 8.93 million shares at $37.50 plus pre-funded warrants. Volume was 2.49 million shares versus a 1.20 million average.

rttnews.com2 min